In vitro modeling of HER2-targeting therapy in disseminated prostate cancer

By          

International Journal of Oncology, Vol. 45, Iss. 5, 2014-01 ,pp. : 2153-2158

Spandidos Publications

Access to resources Recommend Favorite

MYH mutations are rare in prostate cancer

By Shin Eyun-Jung   Chappell Edward   Pethe Vaijayanti   Hersey Karen   Kwast Theodore   Fleshner Neil   Bapat Bharati  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 6, 2007-06 ,pp. : 373-378

Springer Publishing Company

Access to resources Recommend Favorite

Gastric Carcinoma—A Rare Presentation

By Vikram Syam  

Indian Journal of Surgical Oncology, Vol. 1, Iss. 4, 2010-12 ,pp. : 346-348

Springer Publishing Company

Access to resources Recommend Favorite

Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-A''DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines

By      

Experimental and Therapeutic Medicine, Vol. 2, Iss. 3, 2011-01 ,pp. : 523-528

Spandidos Publications

Access to resources Recommend Favorite

Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique

By Johannsen M.   Gneveckow U.   Eckelt L.   Feussner A.   WaldÖFner N.   Scholz R.   Deger S.   Wust P.   Loening S. A.   Jordan A.  

International Journal of Hyperthermia, Vol. 21, Iss. 7, 2005-11 ,pp. : 637-647

Informa Healthcare

Access to resources Recommend Favorite